The latest DDW Sitting Down With podcast features Guy Goldberg, Chief Business Officer of RedHill Biopharma.
RedHill Biopharma is a biopharmaceutical company that recently announced the dosing of the first patient in its US Phase II/III study of orally-administered RHB-107 (upamostat), an investigational new drug for patients with symptomatic COVID-19 who do not require hospital care.
Goldberg talks us through Covid-19 therapeutics and their role in the pandemic.
Listen now to share in his market insight, expertise on developing Covid-19 therapies, the benefits of an orally-administered small molecule tablet for COVID treatment and how the company has achieved and maintained its success in the therapeutics market.
Listen here.
